May 5, 2022 07:21 AM EDT

Enhertu wins another breast cancer approval, as AstraZeneca and Daiichi Sankyo prepare to corner the market

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

view job offer post your job now

TRENDING NOW

To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Dutch biotech gets $146M for late-stage trials in three metabolic disorders

Lack of detail in Trump's drug price plan raises more questions than answers

Pharma investors brush off Trump’s ‘most favored nation’ plan as stocks rise

Updated: White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain